Autoantibodies in lung cancer: Possibilities for early detection and subsequent cure

Thorax

Volumn 63, Issue 3, 2008, Pages 228-233

  Chapman, C J ^a,b   Murray, A ^a   McElveen, J E ^b   Sahin, U ^c   Luxemburger, U ^c   Tureci O ^c   Wiewrodt, R ^c   Barnes, A C ^b   Robertson, J F ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MUCIN 1; MYC PROTEIN; NY ESO 1 ANTIGEN; PROTEIN P53; TUMOR ANTIGEN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD EXAMINATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; AUTOANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUNG NEOPLASMS; MIDDLE AGED;

EID: 40649124272     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.083592     Document Type: Article

References (37)

1. Office for National Statistics. Twentieth century mortality - 95 years of mortality data in England and Wales by age, sex, year and underlying cause. London: Office for National Statistics, 1997 (ISBN 1 857742 397.)
2. Felip E, Pavlidis N, Stahel RA, cooordinating authors for the ESMO guidelines task force. ESMO Minimal Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol 2005;16(suppl 1):i30-1.
3. Felip E, Stahel RA, Pavlidis N, cooordinating authors for the ESMO guidelines task force. ESMO Minimal Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Anns Oncol 2005;16(suppl 1):i28-9.
4. MacRedmond R, McVey G, Lee M, et al. Screening for lung cancer using low dose CT scanning: results of 2 year follow up. Thorax 2006;61:54-6.
5. Ries LAG, Eisner MP, Kosary CL, et al SEER cancer statistics review, 1975-2001. Bethesda, MD: National Cancer Institute.
6. Zhong L, Coe SP, Stromberg AJ, et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thor Oncol 2006;1:513-9.
7. Zhang JY, Casiano CA, Peng XX, et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003;12:136-43.
8. Storr SJ, Chakrabarti J, Barnes A, et al. Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev Anticancer Ther 2006;6:1215-23.
9. Robertson JFR, Chapman C, Cheung K-L, et al. Autoantibodies in early breast cancer. J Clin Oncol 2005;23(Suppl 1):549.
10. Robertson JFR, Graves RL, Price MR, Inventors; OncImmune Ltd, assignee. Tumour markers. European patent EP-B 1078264, 2005.
11. Li Y, Karjalainen A, Koskinen H, et al. p53 Autoantibodies predict subsequent development of cancer. Int J Cancer 2005;114:157-60.
12. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007;18:868-73.
13. Crawford LV, Pim DC, Bulbrook RD. The detection of antibodies against the cellular protein p53 in sera from patients with breast-cancer. Int J Cancer 1982;30:403-8.
14. Sangrajrang S, Sornprom A, Chernrungroj G, et al. Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. Lung Cancer 2003;39:297-301.
15. Li Y, Brandt-Rauf PW, Carney WP, et al. Circulating anti- p53 antibodies in lung cancer and relationship to histology and smoking. Biomarkers 1999;4:381-90.
16. Trivers GE, DeBenedetti VM, Cawley HL, et al. Anti p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996;2:1767-75.
17. Veale D, Ashcroft T, Marsh C, et al. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987;55:513-6.
18. Szelachowska J, Jelen M, Kornafel J. Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer. Anticancer Res 2006;26:3871-6.
19. Awaya H, Takeshima Y, Yamasaki M, et al. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 2004;121:644-53.
20. Hirasawa Y, Kohno N, Yokoyama A, et al. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000;161:589-94.
21. Krause P, Tureci O, Micke P, et al. SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. J Immunol Methods 2003;283:261-7.
22. Türeci O, Mack U, Luxemberger U, et al. Humoral responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 2006;236:64-71.
23. Cho B, Lim Y, Lee DY, et al. Identification and characterization of a novel cancer/ testis antigen gene CAGE. Biochem Biophys Res Commun 2002;292:715-26.
24. Cho B, Lee H, Jeong S, et al. Promotor hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its abberant expression and is seen in premalignant stage of gastric cancer. Biochem Biophys Res Commun 2003;307:52-63.
25. Xia Q, Kong XT, Zhang GA, et al. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun 2005;330:526-32.
26. Tureci O, Usener D, Schneider S, et al. Identification of tumor-associated autoantigens with SEREX. Methods Mol Med 2005;109:137-54.
27. Linder P. Dead-box proteins: a family affair - active and passive players in RNP-remodeling. Nucleic Acids Res 2006;34:4168-80.
28. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning a laboratory manual. ed 2. USA: Cold Spring Harbour Laboratory Press, 1989.
29. Gendler SJ, Spicer AP, Lalani EN, et al. Structure and biology of the carcinoma-associated mucin, MUC1. Am Rev Resp Dis 1991;144:S42-7.
30. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford. UK: Blackwell Science, 2002: 117.
31. Nesterova M, Johnson N, Cheadle C, et al. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006;1762:398-403.
32. Neri M, Betta P, Marroni P, et al. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases. Lung Cancer 2003;39:165-72.
33. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:8055-62.
34. Megliorino R, Shi FD, Peng XX, et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 2005;29:241-8.
35. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001;98:9824-9.
36. Yagihashi A, Asanuma K, Kobayashi D, et al. Detection of autoantibodies to livin and survivin in sera from lung cancer patients. Lung Cancer 2005;48:217-21.
37. Oka M, Sato S, Soda H, et al. Autoantibody to heat shock protein Hsp40 in sera of lung cancer patients. Jpn J Cancer Res 2001;92:316-20.